NCT07001033Completed
Dance Movement Therapy for Radio-oncological Patients
Integrative, Resource-oriented Short Term Dance Movement Therapy for Radio-oncological Patients
Source: ClinicalTrials.gov · Last updated 3 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Dance-RT-01 investigates the feasibility and effects of Integrative, resource-oriented short term Dance Movement Therapy (DMT) in radio-oncological patients shortly after radiotherapy (RT). The study assesses clinical outcomes, including reduction of fatigue, improvement of quality of life (QoL), functional capacity and body composition. Immunophenotyping and laboratory blood analyses ensure objectively measurable results. Eligible patients participate in short term DMT, that is combined with psychotherapeutic elements. The trial aims to evaluate DMT's potential as a complementary therapy method in cancer care to support recovery and provide a comprehensive understanding of the therapy's effects.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 3 Mar 2025
- Start date
- 22 Feb 2025
- Primary completion date
- 20 Apr 2025
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Diseases
- Prostate cancer
- NCT number
- NCT07001033
What you commit to
- Study type: Interventional
- Participants enrolled: 8
- From 22 Feb 2025 to the primary completion date, 20 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Serious concurrent neurologic or psychiatric disorders: dementia, uncontrolled seizures, psychosis, schizophrenia, neurosis, autism that would interfere with cooperation with the requirements of the trial
Other illness
- Familial, sociological, or geographical condition that would preclude study compliance (these conditions should be discussed with the patient before registration in the study)
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Lab values
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the study team
Other
- Inability to speak and understand German
- Is pregnant or breastfeeding, or expecting to conceive
Who the study is looking for
- Male and female oncological patients
- Age at least 18 years. No upper age limit
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Written informed consent for participation in the study
- Prior RT received shortly before study inclusion (therapy completed)
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology, Translational Radiobiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg Coordinator of this site? Confirm its status | Erlangen | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.